WELCOME TO
BSG LIVE’25
Industry Symposia – Alfasigma
This is a promotional event, organised by Alfasigma, for UK healthcare professionals.
Prescribing Information and Adverse Event Reporting Information can be found below.
Deep Dive Into GALOCEAN
Wednesday 24th June 10.35 - 10.55
Deep dive into the early real-world outcomes of an interim analysis of data from the prospective, observational GALOCEAN study.
GALOCEAN is a European, multicentre, prospective, observational study of ~520 patients with UC receiving filgotinib in clinical care, and this symposium will discuss effectiveness and safety data for up to 24 weeks among patients with moderately or severely active UC.
Speaker:
- Professor Jimmy Limdi, Northern Care Alliance NHS Foundation Trust
Estimated Timings:
10:35: Intro
10:40: GALOCEAN
10:50: Summary / Questions
Jyseleca (filgotinib) is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent.
Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk or via the Yellow Card app (download from the Apple App Store or Google Play Store). Adverse events should also be reported to Alfasigma via email to [email protected] or via telephone on 0800 072 7878.
Document Number: UK-UC-FIL-202605-00001
Date of Prep: June 2026
